ENLV Enlivex Therapeutics Ltd

Price (delayed)

$0.1977

Market cap

$3.33M

P/E Ratio

0

Dividend/share

N/A

EPS

$529.4

Enterprise value

$15.06M

?
Relative Growth: Rel. Growth: 28
Relative Strength: Rel. Strength: 0
Relative Valuation: Rel. Valuation: 94
Relative Profitability: Rel. Profitability: 63

Bio Blast Pharma Ltd., a development stage biopharmaceutical company, focuses on the identification, licensing, acquisition, development, and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. The company ...

Key stats

What are the main financial stats of ENLV

ENLV stock price

How has the Enlivex Therapeutics stock price performed over time
Intraday
-2.23%
1 week
-11.82%
1 month
-69.42%
1 year
-98.76%
YTD
-98.13%
QTD
-60.68%

Financial performance

How have Enlivex Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.25M
Net income
$3.19B
Gross margin
N/A
Net margin
N/A
The company's operating income has shrunk by 58% YoY

Price vs fundamentals

How does ENLV's price correlate with its fundamentals

Growth

What is Enlivex Therapeutics's growth rate over time

Valuation

What is Enlivex Therapeutics stock price valuation
P/E
0
P/B
0
P/S
N/A
EV/EBIT
0
EV/EBITDA
0
EV/Sales
N/A
ENLV's P/B is 100% below its 5-year quarterly average of 1.2 and 100% below its last 4 quarters average of 0.7

Efficiency

How efficient is Enlivex Therapeutics business performance
The ROIC has soared by 110% YoY

Dividends

What is ENLV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENLV.

Financial health

How did Enlivex Therapeutics financials performed over time
ENLV's debt is 100% lower than its equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.